Leokadia Głogulska

Leokadia Głogulska is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, space technology and global market developments. She graduated from Wrocław University of Economics and Business and previously worked in financial analysis before moving into business journalism. Her reporting focuses on helping readers understand the market trends, companies and technologies shaping the global economy.

Microsoft, Meta and Apple Results to Gauge If Big Tech Has Cash to Match Soaring AI Costs

Microsoft, Meta and Apple Results to Gauge If Big Tech Has Cash to Match Soaring AI Costs

Microsoft, Meta Platforms, and Apple are set to release their earnings this week as investors appear less responsive to results that surpass expectations. Alphabet demonstrated this change; the Google parent beat revenue projections on Wednesday with 24% growth but still experienced a sharp share drop. Investing.com
1 2 3 27

Stock Market Today

  • Revolution Medicines (RVMD) Shares Trade at a Premium Despite Robust Gains
    July 25, 2026, 2:47 PM EDT. Revolution Medicines (RVMD) shares have jumped with a 399.2% return over the past year and approximately 6.4x growth in three years, though the stock's valuation is considered steep. With a P/B ratio of 26.8x, Revolution Medicines is well above the Biotech sector's 2.5x average and peer level of 10.3x. The stock meets just 2 out of 6 valuation criteria, indicating a premium linked to its FDA-reviewed drug daraxonrasib and data from its pancreatic cancer trial, along with concerns tied to regulatory risk.